>>INCY’s drug might be able to show statsig non-inferiority, which ought to be good enough for FDA approval with a suitable SPA.<< Thanks, Dew. Do you think that's likely given the following? Drug ACR20 minus placebo ACR20: Pfizer: 39% Incyte: 20% Reminder: The ACR20 drug/placebo comparison was Incyte's primary Phase 2B endpoint. micro